This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Centene's Michigan Unit Partners With Mae to Reduce Health Disparities
by Zacks Equity Research
CNC's Meridian unit collaborates with Mae to improve health outcomes and address health disparities in Michigan.
3 Reasons Why Growth Investors Shouldn't Overlook The Pennant Group (PNTG)
by Zacks Equity Research
The Pennant Group (PNTG) could produce exceptional returns because of its solid growth attributes.
DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Centene's Unit Secures New Four-Year Medicaid Contract in Iowa
by Zacks Equity Research
CNC's unit, Iowa Total Care, wins a new contract to provide Medicaid managed care services, enhancing its presence in Iowa and bringing improved health outcomes in the state.
Is The Pennant Group (PNTG) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
The Pennant Group (PNTG) possesses solid growth attributes, which could help it handily outperform the market.
DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Pennant Group (PNTG) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
The Pennant Group (PNTG) could produce exceptional returns because of its solid growth attributes.
Here's What Key Metrics Tell Us About The Pennant Group (PNTG) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for The Pennant Group (PNTG) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 14.29% and 7.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 12.50% and 1.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DGX vs. PNTG: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. PNTG: Which Stock Is the Better Value Option?
Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?
by Zacks Equity Research
Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
The Pennant Group, Inc. (PNTG) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Retain UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of a sound customer base, acquisitions and partnerships, the telehealth services suite, and growing cash reserves.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Compared to Estimates, The Pennant Group (PNTG) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for The Pennant Group (PNTG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Pennant Group, Inc. (PNTG) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 11.11% and 7.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes The Pennant Group, Inc. (PNTG) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?
by Zacks Equity Research
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.